Patient Monitoring & Vital Signs in Texas

Millar LLC is a medical sensor technology company specializing in MEMS (microelectromechanical systems) pressure sensors and related sensing solutions for medical devices and industrial applications. Founded in 1969, Millar has over 55 years of expertise in high-fidelity pressure measurement for acute and chronic monitoring. The company's core product portfolio includes acute pressure sensors (minimally invasive, high-accuracy measurement), chronic pressure sensors (TiSense implantable technology for up to 10-year monitoring in titanium housings), ISFET pH sensors, electrical conductivity (EC) sensors, oxidation-reduction potential (ORP) sensors, temperature sensors, and volume measurement solutions. Millar operates as a Contract Design and Manufacturer (CDMO) providing end-to-end sensor integration services from discovery and proof of concept through prototyping, manufacturing development, design validation, clinical trials, and device commercialization. The company holds ISO 13485 certification and operates an ISO Class 7 clean room facility supporting FDA-approved medical device production. Millar also operates a pure-play MEMS microfoundry for custom sensor fabrication. Primary markets include cardiovascular monitoring, hemodynamic pressure measurement, and OEM medical device integration. The company serves both medical device manufacturers requiring sensor integration and industrial customers requiring environmental and process monitoring solutions. Regulatory credentials include experience with FDA 510(k) pathways and clinical trial support.

Germaine Laboratories, Inc. is an FDA-registered manufacturer and distributor of in vitro diagnostic tests and reagents serving medical, drug testing, veterinary, and food & beverage industries since 1990. The company holds ISO 13485:2016 certification for quality management systems applicable to diagnostic test manufacturing. Product portfolio includes urinalysis reagent strips (AimStrip®), hemoglobin testing systems (AimStrip® Hemoglobin), strep detection tests (StrepAim®), pregnancy tests (AimStep®), blood glucose monitoring systems (VQPet H for veterinary use), COVID-19 antigen home tests (Flowflex™), and reducing substance tablets for food testing (AimTab™). The company serves physician offices, walk-in clinics, pharmacies, hospitals, drug court programs, schools, workplaces, veterinary practices, and food & beverage manufacturers. All products are CLIA-waived where applicable and FDA-approved. Germaine Laboratories operates as both a manufacturer and distributor, offering bulk packaging, private labeling, OEM arrangements, and exclusive distributorship opportunities. The company provides laboratory services and tableting contract manufacturing capabilities. Customer service and technical support are available 24/7 via phone and email, with emphasis on rapid response and order fulfillment.

Integrity Medical Products is a B2B supplier of medical equipment accessories, replacements, and consumables for healthcare facilities. The company specializes in patient monitoring cables and sensors (SpO2, ECG, invasive/non-invasive blood pressure) compatible with major monitor brands, available at 30–60% savings versus OEM pricing, with one-year warranties. Product portfolio includes monitor mounting arms and cable management systems (five-year warranty), nurse call accessories with pillow speakers (two-year warranty), medical carts and stands for monitors, ventilators, and suction pumps, and hospital furniture including overbed tables, bedside cabinets, fetal monitoring carts, bassinets, stools, and chairs with antimicrobial construction. Integrity also supplies suction and oxygen therapy products (analog and digital suction regulators, portable suction pumps, flowmeters, gas regulators, cylinder carts, high-pressure hoses) and offers patent-pending Integrated Flowmeter technology. Additional product lines include diagnostic systems (ophthalmoscopes/otoscopes with Welch Allyn compatibility), endoscopy/OR monitors and video accessories (wireless transmitters, fiber optic light cords, custom screen protectors), operating room table and stretcher pads (gel, foam, and self-adjusting air options for pressure ulcer prevention), and bed and stretcher accessories with custom fabrication available. The company targets hospitals, surgical centers, and critical care facilities, emphasizing affordability, compatibility with existing infrastructure, and practical solutions to institutional procurement challenges.

IDMED develops and markets innovative medical devices for anesthesia and intensive care monitoring. The company specializes in automated pupillometry and neuromuscular transmission (NMT) monitoring solutions used globally in operating rooms and ICU settings. The NeuroLight® pupillometer provides accurate, automated measurement of pupil size and reactivity for neurological assessment and prognostication in intensive care environments. The ToFscan® is a quantitative neuromuscular blockade monitor utilizing three-dimensional sensors with a wide sensor range and requires no pre-use calibration. Both products are designed to enhance clinical decision-making and patient safety in perioperative and critical care settings. IDMED's focus on neurological and neuromuscular monitoring positions the company within the specialty diagnostic and patient monitoring equipment segment, serving anesthesiology, critical care, and neurology departments.

Bluedrop RPM is a remote patient monitoring (RPM) company specializing in diabetic foot ulcer (DFU) prevention and early detection. The company develops at-home foot scanning and monitoring solutions designed for patients with diabetes who are at high risk for peripheral neuropathy-related foot complications. Bluedrop's primary offering is OneStep, a smart-scale foot scanner that captures high-resolution images and thermal data in under 30 seconds per day. The device pairs with EveryStep, a cloud-based monitoring service that analyzes scan data, identifies risk indicators, and communicates findings directly to patients and their healthcare providers when clinical escalation is warranted. The platform emphasizes ease of use and consistent patient engagement to enable early-stage DFU detection, which significantly reduces treatment costs and clinical severity. Bluedrop reports an average patient compliance of approximately 4 scans per week, with detected ulcers graded at Stage 1 upon clinical escalation. The company serves both individual patients seeking convenient at-home foot health management and healthcare providers seeking to reduce preventable complications in their highest-risk diabetic populations. Bluedrop operates with offices in Houston, TX and Galway, Ireland, positioning the company for both North American and European markets.